Shire introduces three additional dosage strengths of Vyvanse in US

According to the company, the expanded Vyvanse dosing options will allow physicians to individualize treatment for each patient. Vyvanse, which received FDA approval for the treatment of attention deficit hyperactivity disorder (ADHD) in children in 2007, was also recently approved to treat ADHD in adults.

Greg Mattingly, associate clinical professor at the department of psychiatry at Washington University School of Medicine in St Louis, Missouri, said: “Vyvanse is a recently approved ADHD treatment option for the adult population. In a clinical study with adults, Vyvanse was shown, within the first week, to significantly improve ADHD symptoms, inattention, such as the ability to focus and organize, and hyperactivity and impulsivity, such as restlessness, and interrupting.”